Intraoperative sentinel lymph node identification in lung cancer

Intraoperative identification of sentinel lymph node using ICG fluorescence in lung cancer - INVENTION study

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs051180061

Enrollment

Registered

2019-02-14

Start date

2019-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary lung cancer

Interventions

During operation, ICG (5mg/m) and autologousblood will be injected around the tumor, and the visualization of sentinel lymph node (SLN) will be attempted using near-infrared (NIR) fluorescence imaging

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Primary lung cancer patients who will receive thoracoscopic lobectomy and mediastinal lympadenectomy. 2. Patients having provided signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who are allergic to iodine, and who are pregnant. 2. Patients who do not consent to informed document.

Design outcomes

Primary

Measure	Time frame
The evaluation of visualization and identification of SLN by using NIR imaging system.	—

Secondary

Measure	Time frame
The comparison of the metastatic status between NIR fluorescence imaged and histopathological results.	—

Contacts

Public ContactShinya Tane

Hyogo Cancer Center

shinyatane@gmail.com+81-78-929-1151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026